Top Strong Buy Stocks for October 31: PMT, NWG, and Others
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2025
0mins
Should l Buy PAHC?
Source: NASDAQ.COM
Zacks Rank #1 Stocks: Five stocks have been added to the Zacks Rank #1 (Strong Buy) List, including PennyMac Mortgage Investment Trust, NatWest Group, Phibro Animal Health, Centene, and ACNB, all of which have seen positive earnings estimate revisions over the past 60 days.
Earnings Growth: Each of the highlighted companies has experienced an increase in the Zacks Consensus Estimate for their current year earnings, with PennyMac leading at 10.3% growth.
Investment Opportunities: The article suggests that these stocks are under the radar of Wall Street, presenting a unique opportunity for investors to potentially capitalize on significant growth, with previous recommendations yielding returns of +171%, +209%, and +232%.
Expert Recommendations: Zacks Investment Research offers a free report on the "7 Best Stocks for the Next 30 Days," encouraging investors to consider these handpicked stocks for potential high returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAHC
Wall Street analysts forecast PAHC stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 53.880
Low
45.00
Averages
47.50
High
50.00
Current: 53.880
Low
45.00
Averages
47.50
High
50.00
About PAHC
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 750 product lines in over 80 countries to approximately 4,200 customers. It has three segments: Animal Health, Mineral Nutrition and Performance Products. Its Animal Health segment develops, manufactures and markets about 280 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. The Mineral Nutrition segment is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. The Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
- Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
- Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
- Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
- Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
See More
Form 144: Phibro Animal Health (PAHC.US) 10% Stakeholder Plans to Sell $12.19 Million in Common Shares
Stock Sale Announcement: BFI Co. LLC plans to sell 246.4K shares of its common stock in Phibro Animal Health (PAHC.US), valued at approximately $12.19 million.
Reduction in Shareholding: BFI Co. LLC has decreased its shareholding in Phibro Animal Health by 302.72K shares since January 7, 2026, with a total value of around $14.54 million.
See More
Phibro Animal Health CEO Executes Share Sale Amid Strong Performance
- Executive Share Sale: Jack Bendheim, CEO of Phibro Animal Health Corporation, sold 14,080 shares of common stock through indirect open-market transactions on February 13 and 18, 2026, for total proceeds of approximately $728,000, indicating proactive management of executive holdings.
- Ownership Analysis: Post-transaction, Bendheim retains 16,840 shares directly and 36,680 shares indirectly, totaling 53,520 shares, suggesting a continued optimistic outlook on the company's future without an immediate rush to liquidate his holdings.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan adopted in May 2025, aimed at avoiding insider trading allegations, highlighting the executive's commitment to transparency and compliance.
- Company Performance Highlights: Phibro reported a 21% year-over-year revenue increase in its fiscal Q2 2026, reaching $373.9 million, and raised its full-year revenue guidance to between $1.45 billion and $1.50 billion, reflecting strong performance in the animal health sector.
See More
Jack Bendheim's Executive Update
- Executive Leadership Update: Jack Bendheim continues to serve as the company's Director, President, and CEO as of February 24, 2026, holding a 10% ownership stake, reflecting his ongoing commitment and leadership.
- Governance Stability: Bendheim's continued role helps maintain governance stability, ensuring consistency in strategic direction, which in turn enhances investor confidence.
- Market Reaction Expectations: While specific financial data is not disclosed, Bendheim's leadership experience may positively impact the company's future market performance, especially in uncertain economic conditions.
- Strategic Development Potential: Under Bendheim's leadership, the company is poised to achieve strategic development goals, further enhancing its market competitiveness and business growth potential.
See More
Phibro Animal Health CEO Sells 72,198 Shares in Open Market
- Executive Sale Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating sustained confidence in the company's stock despite the sale.
- Ownership Impact: The transaction resulted in approximately 51.64% of Bendheim's total holdings (both direct and indirect) being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting the executive's sensitivity to market dynamics.
- Transaction Context: This sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating a strategic approach to risk management amidst market fluctuations.
- Company Performance Outlook: Phibro's Q2 fiscal year 2026 earnings report showed year-over-year growth in revenue, net income, and earnings per share, with the CEO expressing confidence in future performance, particularly in the demand for its nutrition products and vaccines, which are expected to drive long-term growth.
See More
Phibro Animal Health CEO Sells 72,198 Shares After Strong Q2 2026 Performance
- Transaction Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating confidence in the company's future prospects.
- Ownership Impact: This transaction resulted in approximately 51.64% of Bendheim's total holdings being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting sensitivity to market dynamics.
- Trading Plan Context: The sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating that Bendheim's actions were not influenced by recent company news, thus maintaining transparency.
- Company Performance Highlights: Phibro reported year-over-year revenue growth in its Q2 2026 earnings, with net income reaching $92.09 million, underscoring strong demand for its animal nutrition products and vaccines, suggesting promising future growth potential.
See More
Omnicell Advances Vision of Autonomous Pharmacy Amid Challenges
- Vision for Autonomous Pharmacy: Omnicell is committed to advancing the industry-defined vision of the autonomous pharmacy, aiming for zero-error medication management by enhancing operational efficiencies, having expanded from a single-point solution to a diversified product platform over recent years, thereby strengthening its market competitiveness.
- Expansion of SaaS and Expert Services: The company is steadily increasing revenue from its SaaS and Expert Services through acquisitions and new platform launches, with several health systems committing to its inventory optimization service in Q4 2025, indicating robust market demand.
- Strong Financial Health: As of Q4 2025, Omnicell reported cash and cash equivalents of $197 million against total debt of $168 million, reflecting a solid solvency position with a debt-to-capital ratio reduced to 12.1%, which supports future investments and expansion.
- Cost Pressures Impacting Margins: Despite successes in various sectors, Omnicell faced challenges from labor shortages and rising raw material costs, leading to a year-over-year decline of approximately 4 percentage points in non-GAAP gross margin in Q4 2025, which may strain profit margins.
See More
Form 144: Phibro Animal Health (PAHC.US) 10% Stakeholder Plans to Sell $12.19 Million in Common Shares
Stock Sale Announcement: BFI Co. LLC plans to sell 246.4K shares of its common stock in Phibro Animal Health (PAHC.US), valued at approximately $12.19 million.
Reduction in Shareholding: BFI Co. LLC has decreased its shareholding in Phibro Animal Health by 302.72K shares since January 7, 2026, with a total value of around $14.54 million.
See More
Phibro Animal Health CEO Executes Share Sale Amid Strong Performance
- Executive Share Sale: Jack Bendheim, CEO of Phibro Animal Health Corporation, sold 14,080 shares of common stock through indirect open-market transactions on February 13 and 18, 2026, for total proceeds of approximately $728,000, indicating proactive management of executive holdings.
- Ownership Analysis: Post-transaction, Bendheim retains 16,840 shares directly and 36,680 shares indirectly, totaling 53,520 shares, suggesting a continued optimistic outlook on the company's future without an immediate rush to liquidate his holdings.
- Transaction Context: This sale was executed under a Rule 10b5-1 trading plan adopted in May 2025, aimed at avoiding insider trading allegations, highlighting the executive's commitment to transparency and compliance.
- Company Performance Highlights: Phibro reported a 21% year-over-year revenue increase in its fiscal Q2 2026, reaching $373.9 million, and raised its full-year revenue guidance to between $1.45 billion and $1.50 billion, reflecting strong performance in the animal health sector.
See More
Jack Bendheim's Executive Update
- Executive Leadership Update: Jack Bendheim continues to serve as the company's Director, President, and CEO as of February 24, 2026, holding a 10% ownership stake, reflecting his ongoing commitment and leadership.
- Governance Stability: Bendheim's continued role helps maintain governance stability, ensuring consistency in strategic direction, which in turn enhances investor confidence.
- Market Reaction Expectations: While specific financial data is not disclosed, Bendheim's leadership experience may positively impact the company's future market performance, especially in uncertain economic conditions.
- Strategic Development Potential: Under Bendheim's leadership, the company is poised to achieve strategic development goals, further enhancing its market competitiveness and business growth potential.
See More
Phibro Animal Health CEO Sells 72,198 Shares in Open Market
- Executive Sale Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating sustained confidence in the company's stock despite the sale.
- Ownership Impact: The transaction resulted in approximately 51.64% of Bendheim's total holdings (both direct and indirect) being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting the executive's sensitivity to market dynamics.
- Transaction Context: This sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating a strategic approach to risk management amidst market fluctuations.
- Company Performance Outlook: Phibro's Q2 fiscal year 2026 earnings report showed year-over-year growth in revenue, net income, and earnings per share, with the CEO expressing confidence in future performance, particularly in the demand for its nutrition products and vaccines, which are expected to drive long-term growth.
See More
Phibro Animal Health CEO Sells 72,198 Shares After Strong Q2 2026 Performance
- Transaction Overview: Jack Bendheim, CEO of Phibro Animal Health, sold 72,198 shares in multiple open-market transactions between February 10 and 11, 2026, totaling approximately $3.74 million, indicating confidence in the company's future prospects.
- Ownership Impact: This transaction resulted in approximately 51.64% of Bendheim's total holdings being disposed of, with the indirect account (BFI Co. LLC) experiencing a significant 58.72% reduction, reflecting sensitivity to market dynamics.
- Trading Plan Context: The sale was executed under a pre-existing Rule 10b5-1 trading plan at a weighted average price of around $51.77 per share, indicating that Bendheim's actions were not influenced by recent company news, thus maintaining transparency.
- Company Performance Highlights: Phibro reported year-over-year revenue growth in its Q2 2026 earnings, with net income reaching $92.09 million, underscoring strong demand for its animal nutrition products and vaccines, suggesting promising future growth potential.
See More
